Association Of Mapk Signaling Subtypes With Prognostic Benefit For Bevacizumab In Left-Sided Metastatic Colorectal Cancer (Mcrc) Patients Treated With Folfiri Plus Cetuximab / Bevacizumab (Fire-3 Trial).
JOURNAL OF CLINICAL ONCOLOGY（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络